Clinical trial
Predictors for Response to Dose-dense Docetaxel and Epirubicin Breast Cancer
NCT00496795 · University of Bergen, Other · Active, not recruiting
Key facts
| NCT number | NCT00496795 |
|---|---|
| Title | Predictors for Response to Dose-dense Docetaxel and Epirubicin Breast Cancer |
| Official title | Molecular Markers Predictive Response to Dose Dense Chemotherapy With Epirubicin and Docetaxel in Sequences for Locally Advanced Breast Cancer. |
| Acronym | DDP |
| Lead sponsor | University of Bergen, Other |
| Collaborators | Haukeland University Hospital |
| Status | Active, not recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Stage III Breast Cancer AJCC V7 |
| Intervention type | Other |
| Interventions | epirubicin/docetaxel sequential |
| Enrollment | 100 |
| Start date | Sep 1, 2007 |
| Primary completion | May 1, 2016 |
| Completion | May 1, 2026 |
| First posted | Jul 4, 2007 |
| Last update posted | Jun 29, 2022 |
| Countries | Norway |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: